338 related articles for article (PubMed ID: 15090448)
21. Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival.
Ho PJ; Brown RD; Pelka GJ; Basten A; Gibson J; Joshua DE
Blood; 2001 Jan; 97(2):490-5. PubMed ID: 11154227
[TBL] [Abstract][Full Text] [Related]
22. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
Fonseca R; Bailey RJ; Ahmann GJ; Rajkumar SV; Hoyer JD; Lust JA; Kyle RA; Gertz MA; Greipp PR; Dewald GW
Blood; 2002 Aug; 100(4):1417-24. PubMed ID: 12149226
[TBL] [Abstract][Full Text] [Related]
23. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.
Rasmussen T; Theilgaard-Mönch K; Hudlebusch HR; Lodahl M; Johnsen HE; Dahl IM
Br J Haematol; 2003 Oct; 123(2):253-62. PubMed ID: 14531906
[TBL] [Abstract][Full Text] [Related]
24. Oligonucleotide-based array CGH as a diagnostic tool in multiple myeloma patients.
Smetana J; Fröhlich J; Vranová V; Mikulásová A; Kuglik P; Hájek R
Klin Onkol; 2011; 24 Suppl():S43-8. PubMed ID: 21923064
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
[TBL] [Abstract][Full Text] [Related]
26. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
27. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetics and molecular cytogenetics in multiple myeloma.
Liebisch P; Döhner H
Eur J Cancer; 2006 Jul; 42(11):1520-9. PubMed ID: 16781866
[TBL] [Abstract][Full Text] [Related]
29. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
[TBL] [Abstract][Full Text] [Related]
30. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.
Chesi M; Bergsagel PL; Brents LA; Smith CM; Gerhard DS; Kuehl WM
Blood; 1996 Jul; 88(2):674-81. PubMed ID: 8695815
[TBL] [Abstract][Full Text] [Related]
31. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.
Richelda R; Ronchetti D; Baldini L; Cro L; Viggiano L; Marzella R; Rocchi M; Otsuki T; Lombardi L; Maiolo AT; Neri A
Blood; 1997 Nov; 90(10):4062-70. PubMed ID: 9354676
[TBL] [Abstract][Full Text] [Related]
32. MMSET: role and therapeutic opportunities in multiple myeloma.
Xie Z; Chng WJ
Biomed Res Int; 2014; 2014():636514. PubMed ID: 25093175
[TBL] [Abstract][Full Text] [Related]
33. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
Chesi M; Bergsagel PL; Shonukan OO; Martelli ML; Brents LA; Chen T; Schröck E; Ried T; Kuehl WM
Blood; 1998 Jun; 91(12):4457-63. PubMed ID: 9616139
[TBL] [Abstract][Full Text] [Related]
34. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.
Finelli P; Fabris S; Zagano S; Baldini L; Intini D; Nobili L; Lombardi L; Maiolo AT; Neri A
Blood; 1999 Jul; 94(2):724-32. PubMed ID: 10397739
[TBL] [Abstract][Full Text] [Related]
35. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.
Gabrea A; Bergsagel PL; Chesi M; Shou Y; Kuehl WM
Mol Cell; 1999 Jan; 3(1):119-23. PubMed ID: 10024885
[TBL] [Abstract][Full Text] [Related]
36. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
Glassford J; Rabin N; Lam EW; Yong KL
Br J Haematol; 2007 Oct; 139(2):243-54. PubMed ID: 17897300
[TBL] [Abstract][Full Text] [Related]
37. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.
Sáez B; Martín-Subero JI; Lahortiga I; Largo C; Larrayoz MJ; Odero MD; Prosper F; Cigudosa JC; Siebert R; Calasanz MJ
Cancer Genet Cytogenet; 2007 May; 175(1):65-8. PubMed ID: 17498561
[TBL] [Abstract][Full Text] [Related]
39. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
40. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
Bergsagel PL; Chesi M; Nardini E; Brents LA; Kirby SL; Kuehl WM
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13931-6. PubMed ID: 8943038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
